NewcelX Ltd. (NCEL)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 133 |
| Operating profit | $m | -2 | -7 | ||||||
| Net profit | $m | -3 | -12 | -16 | -12 | -2 | -8 | - | -5 |
| EPS reported | $ | -2.16 | 0.63 | ||||||
| Operating cashflow per share | $ | -0.72 | -0.62 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -0.72 | -0.62 | ||||||
| Free cash flow | $m | -3 | -3 | ||||||
| Net debt | $m | -2 | -0 | ||||||
| Book value equity | $m | 7 | 6 | ||||||
| Book value per share | $ | 1.89 | 1.03 | ||||||
| Number of shares | m | 3.84 | 5.86 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.01 | 1.21 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -2.63 | -2.54 | ||||||
| EV/EBITDA LTM | x | -2.44 | -1.43 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -1.14% | +18.87% | ||||||
| FCF Yield | % | -37.98% | -39.35% | ||||||
| Quality | |||||||||
| ROE | % | -114.48% | +41.94% | ||||||
| ROIC | % | -32.53% | -75.27% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -7.81 | -7.33 | ||||||
| Net Debt/EBITDA | x | 0.83 | 0.57 | ||||||
| EBIT/Net interest | x | -0.41 | -15,269.76 | ||||||
| Net debt/market cap | % | +4.86% | +23.58% | ||||||
| Net debt/Equity | x | -0.25 | -0.05 | ||||||
| Gross debt/equity | x | 0.05 | 0.06 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free